Variables | Disease-specific survival | Overall survival | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||||||
HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | HR | 95% CI | P value | |
Age at RC | ||||||||||||
≤ 70 | 1 | 1 | ||||||||||
> 70 | 1.9 | 0.8–4.2 | 0.12 | 1.7 | 0.8–3.3 | 0.15 | ||||||
Sex | ||||||||||||
Male | 1 | 1 | ||||||||||
Female | 1.4 | 0.5–3.8 | 0.52 | 1.3 | 0.5–3.0 | 0.57 | ||||||
Clinical T | ||||||||||||
NMIBC | 1 | 1 | 1 | 1 | ||||||||
T2 | 3.1 | 0.2–39.7 | 0.38 | 0.8 | 0.09–7.0 | 0.84 | 1.3 | 0.2–8.2 | 0.8 | 1.3 | 0.2–11.5 | 0.78 |
T3 | 3.5 | 0.2–54.0 | 0.36 | 0.7 | 0.08–6.7 | 0.72 | 1.1 | 0.2–9.2 | 0.9 | 0.97 | 0.2–4.9 | 0.98 |
T4 | 4.0 | 1.2–13.7 | 0.03 | 4.1 | 0.5–35.4 | 0.20 | 3.1 | 1.1–8.8 | 0.04 | 6.7 | 0.8–56.9 | 0.08 |
Clinical N | ||||||||||||
N0 | 1 | 1 | 1 | 1 | ||||||||
N+ | 11.3 | 2.8–45.7 | 0.0006 | 3.1 | 1.2–7.8 | 0.02 | 3.9 | 1.2–12.5 | 0.02 | 1.9 | 0.8–4.5 | 0.15 |
Variant histology | ||||||||||||
Negative | 1 | 1 | ||||||||||
Positive | 0.9 | 0.3–2.2 | 0.76 | 0.9 | 0.4–1.9 | 0.73 | ||||||
Neoadjuvant chemotherapy | ||||||||||||
No | 1 | 1 | ||||||||||
Yes | 0.7 | 0.3–1.5 | 0.35 | 0.7 | 0.3–1.5 | 0.35 | ||||||
Adjuvant chemotherapy | ||||||||||||
No | 1 | 1 | ||||||||||
Yes | 1.8 | 0.6–5.3 | 0.28 | 0.7 | 0.4–1.4 | 0.72 | ||||||
Sarcopenia status † | ||||||||||||
No | 1 | 1 | 1 | 1 | ||||||||
Yes | 2.7 | 1.1–7.2 | 0.048 | 1.9 | 0.8–4.5 | 0.14 | 2.3 | 1.1–5.3 | 0.046 | 2.2 | 1.1–4.6 | 0.03 |
Psoas major muscle loss | ||||||||||||
> −10% | 1 | 1 | 1 | 1 | ||||||||
≤ −10% | 2.2 | 0.99–4.8 | 0.052 | 2.0 | 0.9–4.7 | 0.11 | 2.2 | 1.2–4.4 | 0.02 | 2.4 | 1.2–4.9 | 0.02 |